Given that substrate accumulation is the common pathological consequence in both GD and Sap C deficiency, we hypothesized that SRT with Eliglustat, a potent glucosylceramide synthase inhibitor, could also benefit patients with Sap C deficiency. This evidence concerns the gene CCSAP and hyperinsulinemic hypoglycemia, familial, 4.